Aranesp

Type: Product
Name: Aranesp
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Cipla collaborates with Hetero to launch its second biosimilar drug Darbepoetin alfa

Is indicated for the treatment of anaemia caused due to chronic kidney diseaseCipla has collaborated with Hetero to launch a biosimilar of the drug Darbepoetin alfa under the brand name ‘Actorise’. The collaboration stands as a multi-partner co-marketing ... [Published Express Pharma - Jul 07 2014]
First reported Jun 30 2014 - Updated Jul 01 2014 - 1 reports

Cipla links with Hetero for biosimilar Aranesp; M&A in Yemen

Cipla (BSE: 500087) has collaborated with fellow Indian drugmaker Hetero to launch a biosimilar of the drug darbepoetin alfa, US biotech major Amgen's (Nasdaq: AMGN) anemia drug Aranesp, under the brand name Actorise.The collaboration stands as a multi-partner ... [Published Pharma Letter - Jun 30 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

Hetero Launches Darbepoetin Alfa, a Much Needed Biosimilar Anemia Treatment in India

India PRwire2014-06-24The Hetero Group, one of the largest manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) to the Indian pharmaceutical industry, today announced the launch of its first biosimilar product in India, darbepoetin ... [Published BizWire Express - Jun 24 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

Sensex, Nifty drag as oil PSUs cool further

Finally, the Sensex closed at 25,193, down 54 points, while NSE Nifty closed at 7,541, down 18 points. The Indian equity market ended with losses for second consecutive trading session on Thursday. Today’s decline was led by the Oil & gas stocks, especially ... [Published India Infoline - Jun 20 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 2 reports

Indian stock market and companies daily report (June 20, 2014, Friday)

ets are expected to open with a positive bias tracking positive opening in SGX Nifty and most of the Asian markets.After trending higher in the past few sessions, US stocks fluctuated over the course of the trading day on Thursday. The major averages ... [Published Stock Markets Review - Jun 20 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

Indices remain flat; ONGC gains 1.5%

Markets continue to remain range bound. The 30-share Sensex was up 4 points and the 50-share Nifty was up 2 points at 25,207 and 7,542 level, respectively.The broader markets are moving in tandem with their Largecap counterparts. BSE Mid-cap and BSE Small-cap ... [Published Business Standard India - Jun 20 2014]
First reported Jun 18 2014 - Updated Jun 19 2014 - 11 reports

Cipla, Hetero to roll out biosimilar drug

With a second marketing alliance for a biosimilar drug on the cards, drugmaker Cipla is looking to build its pipeline through in-house generated products or similar marketing opportunities, said Jaideep Gogtay, Cipla’s Chief Medical Officer, following ... [Published Hindu Business Line - Jun 19 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Indian Shares Drift Lower Despite Fed Boost

Indian shares fell for a second consecutive session on Thursday as rising crude prices amid ongoing geopolitical tensions in Iraq kept investors nervous. Moody's Investors Service has said that India's high fiscal deficit hurts growth by limiting the ... [Published RTTNews.com - Jun 19 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 1 reports

Omontys terminal as Takeda switches off support

Takeda confirmed today it was ending its partnership with Affymax over troubled anaemia treatment Omontys, which was linked to several deaths last year.The Japanese pharma company was forced to recall several lots of Omontys (peginasetide) in the US after ... [Published PMLive - Jun 16 2014]
First reported Jun 13 2014 - Updated Jun 13 2014 - 1 reports

Analyst: Amgen's moonshot R&D spending is bad for business

Amgen ($AMGN) is hardly gun shy about high-risk, high-reward R&D bets, but the Big Biotech's swing-for-the-fences approach to research is bad for the bottom line, according to Bernstein analyst Geoffrey Porges. Already pushing for a breakup à la Abbott ... [Published FierceBiotech - Jun 13 2014]
First reported Jun 09 2014 - Updated Jun 09 2014 - 1 reports

Preemption. Beautiful, Beautiful Preemption

The test for determining whether a state law claim is impliedly preempted is whether or not the claim would exist in the absence of the FDCA. Rarely do we drug and device law bloggers read such a pleasing sentence.  It’s lyrical.  It reads like romance ... [Published Drug and Device Law - Jun 09 2014]
First reported Jun 02 2014 - Updated Jun 02 2014 - 1 reports

Kite Pharma Names David Chang, M.D., Ph.D., To Lead R&D Programs

PR NewswireSANTA MONICA, Calif., June 2, 2014 SANTA MONICA, Calif."David's accomplishments in the biotech industry align closely with our mission to innovate breakthrough, personalized approaches addressing unmet needs in cancer care," commented Dr. Arie ... [Published Digital Journal - Jun 02 2014]

Quotes

Dr. BPS Reddy, Hetero Group's Chairman and founder, noted, "Hetero's launch of this biosimilar in India demonstrates both our leadership in new biopharmaceutical technologies, and our commitment to improving patient treatment options. Less than five years ago, Hetero first launched its biosimilar effort by building a state of the art R&D and manufacturing facility in Jedcherla, near Hyderabad. For the large number of patients undergoing regular dialysis treatment, darbepoetin alfa's efficacy and safety, coupled with its once weekly dosing are expected to contribute to improved compliance rates and therapeutic outcomes. We look forward to continued collaboration with our commercial partners as we bring the darbepoetin alfa biosimilar to the service of physicians and patients."
Commenting on the current situation, Amar Ambani, Head of Research at IIFL said, "Oil stocks have seen heavy selling in the past couple of days as crude oil prices have surged on the Iraq geo political issue as well as sharp rupee depreciation. Both these factors are expected to result in higher gross under recoveries putting a threat to the reforms that are anticipated in the sector. To add to the woes, media reports suggested that the gas price hike might be available only for the incremental production from current levels. While geo-political tensions will take their own course, clarity on gas price hike is expected in the near term. Reliance Industries continues to be our top pick in the sector."
...to partner with companies in India and around the world to bring wider access of biosimilar products to patients in need," Gogtay commented, adding "therefore, we anticipate more number of deals across therapy areas in near future."
"The collaboration stands as a multi-partner co- marketing deal which offers Cipla a license to make the drug accessible to a wide number of patients in India" the company said in a statement

More Content

All (33) | News (30) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Cipla collaborates with Hetero to launch its se... [Published Express Pharma - Jul 07 2014]
Cipla links with Hetero for biosimilar Aranesp;... [Published Pharma Letter - Jun 30 2014]
Hetero Launches Darbepoetin Alfa, a Much Needed... [Published BizWire Express - Jun 24 2014]
Indian stock market and companies daily report ... [Published Stock Markets Review - Jun 20 2014]
Indices remain flat; ONGC gains 1.5% [Published Business Standard India - Jun 20 2014]
Sensex, Nifty drag as oil PSUs cool further [Published India Infoline - Jun 20 2014]
Cipla to Partner with Hetero to Make Anaemia Bi... [Published FDA News - Jun 20 2014]
Cipla, Hetero to roll out biosimilar drug [Published Hindu Business Line - Jun 19 2014]
Cipla, Hetero team up to market second biosimil... [Published FirstWord Pharma - Jun 19 2014]
Indian Shares Drift Lower Despite Fed Boost [Published RTTNews.com - Jun 19 2014]
Cipla inks pact with Hetero to launch Darbepoet... [Published Indian-Commodity - Jun 19 2014]
Cipla rises on the buzz of inking pact with Het... [Published Arihant Capital - Jun 19 2014]
Cipla to launch biosimilar anaemia drug via Het... [Published Moneycontrol.com - Jun 19 2014]
Cipla partners with Hetero to launch biosimilar... [Published Business Standard India - Jun 19 2014]
Cipla ties up with Hetero to launch second bios... [Published Business Standard India - Jun 19 2014]
Cipla, Hetero team up to market second biosimil... [Published Hindu Business Line - Jun 19 2014]
Cipla collaborates with Hetero to launch second... [Published India Infoline - Jun 19 2014]
Hetero Launches Darbepoetin Alfa, a Much Needed... [Published MarketWired - Jun 18 2014]
Hetero Launches Darbepoetin Alfa, a Much Needed... [Published Marketwire - Breaking News Releases - Jun 18 2014]
Omontys terminal as Takeda switches off support [Published PMLive - Jun 16 2014]
Analyst: Amgen's moonshot R&D spending is bad f... [Published FierceBiotech - Jun 13 2014]
Preemption. Beautiful, Beautiful Preemption [Published Drug and Device Law - Jun 09 2014]
Akebia, Trading M&A For an IPO, Follows Fast in... [Published Xconomy - Jun 09 2014]
Safety of Medical Therapy in Patients With CKD ... [Published General Medicine eJournal - Jun 09 2014]
Amgen to make evolucumab in Juncos [Published Caribbean Business Online - Jun 05 2014]
Kite Pharma Names David Chang, M.D., Ph.D., To ... [Published Digital Journal - Jun 02 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Apr 16 2014]
Amgen net rises by 30% to $1,021 mn in Q4 [Published PharmaBiz - Jan 30 2014]
Methods and compositions for targeting agents i... [Published PharmCast - Jan 05 2014]
The Corporate Whistleblower Center Now Urges Lo... [Published PRWeb - Oct 16 2013]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Hetero Launches Darbepoetin Alfa, a Much Needed... [Published Marketwire - Breaking News Releases - Jun 18 2014]
HYDERABAD, INDIA--(Marketwired - Jun 18, 2014) - The Hetero Group, one of the largest manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) to the Indian pharmaceutical industry, today announced the launch of its first biosimilar product ...
Preemption. Beautiful, Beautiful Preemption [Published Drug and Device Law - Jun 09 2014]
The test for determining whether a state law claim is impliedly preempted is whether or not the claim would exist in the absence of the FDCA. Rarely do we drug and device law bloggers read such a pleasing sentence.  It’s lyrical.  It reads like romance ...
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Apr 16 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.